Skip to main content

Hikma introduces daunorubicin HCl injection

Hikma Pharmaceuticals has launched daunorubicin HCl injection in 20 mg/4 ml and 50 mg/10 ml dosage strengths.

Hikma’s daunorubicin HCl injection is indicated in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia — myelogenous, monocytic, erythroid — of adults and for remission induction in acute lymphocytic leukemia of children and adults.

The product’s market value was approximately $9 million in the 12 months ended May 2018, according to IQVIA.
This ad will auto-close in 10 seconds